Tech Company Inital Public Offerings
Agios Pharmaceuticals IPO
Agios Pharmaceuticals was acquired by . Shares were listed on 7/24/2013.
Transaction Overview
Company Name
Announced On
7/24/2013
Transaction Type
IPO
Amount
$106,200,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
88 Sidney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Agios (NASDAQ: AGIO) is a biopharmaceutical company at the forefront of one of the most exciting new areas of cancer research: cancer metabolism. Cancer metabolism represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacqualyn Fouse
Chief Financial Officer
Andrew Hirsch
Chief Medical Officer
Chris Bowden
Chief Scientific Officer
Scott Biller
VP - Human Resources
Melissa McLaughlin
VP - Marketing
Darrin Miles
VP - Operations
Clive Patience
Browse more venture capital transactions:
Prev: 7/24/2013: Deem venture capital transaction
Next: 7/24/2013: Springbot venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs